Mahoney, Kathleen M.
Rennert, Paul D.
Freeman, Gordon J.
Article History
First Online: 31 July 2015
Competing interests
: G.J.F. has patents pending royalties on the programmed cell death protein 1 (PD1) pathway from Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, and Novartis. G.J.F. has served on advisory boards for CoStim, Novartis, Roche, and Bristol-Myers Squibb. K.M.M. and P.D.R. declare no competing interests.